The surprise election of Donald Trump as President of the United States has thrown greater uncertainty into many industries and individual companies on the receiving end of his verbal comments during speeches, interviews, and tweets. One industry in particular has received special attention – US pharma. President Trump’s comments about the high price of drugs, allowing direct federal government involvement in negotiating drug prices for Medicare, to telling company CEOs that they must manufacture drugs in the United States, add to the already daunting challenges and uncertainties facing industry executives.
However, drug pricing, while important, is just one area of potential impact. President Trump’s policies on areas such as regulation, taxes, international trade, and ACA reform can also have significant effects. A more comprehensive look needs to be taken to understand the full effects of potential policy actions.
Therefore, this white paper is the start of a two-part series that will address in a unique in-depth manner the following questions on the minds of many biopharmaceutical executives:
|(1)||Part 1 - Why has a Trump presidency targeted the biopharma industry?|
|(2)||Part 1 - How could a Trump presidency affect the US biopharma industry through specific policy actions?|
|(3)||Part 2 - What if anything can individual companies do to prepare themselves against these policy actions?|
|(4)||Part 2 - What if any role is there for the use of commercial analytics in assisting companies to mitigate the increased risk and uncertainty caused by these policy actions?|
This paper was co-published with The Medicine Maker.
Dr. George A. Chressanthis is currently Principal Scientist at Axtria. He brings a unique combination of professional experiences into the analysis of strategic and operational issues affecting the biopharmaceutical industry.
Complete the brief form to download the white paper.
Contact us at firstname.lastname@example.org with any questions.